US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.320
+0.120 (+3.75%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
32
33
Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
March 17, 2023
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
March 17, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes
March 14, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension
March 10, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories
March 08, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories
March 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology
March 07, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
↗
March 02, 2023
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in
Via
Benzinga
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
March 02, 2023
Via
ACCESSWIRE
$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying
↗
February 28, 2023
The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested...
Via
Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD
February 27, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology
February 23, 2023
Via
Investor Brand Network
Topics
Economy
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study
February 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study
February 21, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD
↗
February 21, 2023
Via
Benzinga
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 21, 2023
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities
February 21, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities
February 21, 2023
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin
February 17, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin
February 17, 2023
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels
February 10, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels
February 10, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study
February 10, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform
February 08, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year
February 06, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%
February 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience: Charting a Path to Commercial Success
January 31, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
32
33
Next >
